\BOOKMARK [0][-]{chapter.1}{Review of computational drug repositioning approaches}{}% 1
\BOOKMARK [1][-]{section.1.1}{Relevance of drug repositioning}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{Opportunities for finding new indications}{section.1.1}% 3
\BOOKMARK [2][-]{subsection.1.1.2}{Drug repositioning faces legal and scientific challenges}{section.1.1}% 4
\BOOKMARK [1][-]{section.1.2}{Drug repositioning and indication discovery: success stories}{chapter.1}% 5
\BOOKMARK [2][-]{subsection.1.2.1}{Sildenafil: repositioning from clinical side-effects}{section.1.2}% 6
\BOOKMARK [2][-]{subsection.1.2.2}{Thalidomide: repositioning a hazardous drug}{section.1.2}% 7
\BOOKMARK [2][-]{subsection.1.2.3}{Raloxifene: expanding the application line}{section.1.2}% 8
\BOOKMARK [1][-]{section.1.3}{Computational approaches towards drug repositioning}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.3.1}{Chemical structure-based approaches}{section.1.3}% 10
\BOOKMARK [2][-]{subsection.1.3.2}{Gene expression and functional genomics-based approaches}{section.1.3}% 11
\BOOKMARK [2][-]{subsection.1.3.3}{Protein structure and molecular docking-based approaches}{section.1.3}% 12
\BOOKMARK [2][-]{subsection.1.3.4}{Phenotype and side-effect-based approaches}{section.1.3}% 13
\BOOKMARK [2][-]{subsection.1.3.5}{Genetic variation-based approaches}{section.1.3}% 14
\BOOKMARK [2][-]{subsection.1.3.6}{Disease network-based approaches}{section.1.3}% 15
\BOOKMARK [2][-]{subsection.1.3.7}{Machine learning and concepts combination approaches}{section.1.3}% 16
\BOOKMARK [2][-]{subsection.1.3.8}{Summary}{section.1.3}% 17
\BOOKMARK [1][-]{section.1.4}{Thesis: biological process and molecular function for drug repositioning}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.4.1}{Rationale}{section.1.4}% 19
\BOOKMARK [2][-]{subsection.1.4.2}{Towards the specification, implementation and analysis}{section.1.4}% 20
\BOOKMARK [3][-]{subsubsection.1.4.2.1}{Chapter 2 - Description logics and biomedical knowledge \(Specification\)}{subsection.1.4.2}% 21
\BOOKMARK [3][-]{subsubsection.1.4.2.2}{Chapter 3 - The Functional Therapeutic Chemical Classification System \(Implementation\)}{subsection.1.4.2}% 22
\BOOKMARK [3][-]{subsubsection.1.4.2.3}{Chapter 4 - Systematic drug repositioning analysis}{subsection.1.4.2}% 23
\BOOKMARK [3][-]{subsubsection.1.4.2.4}{Chapter 5 - Outlook and future work}{subsection.1.4.2}% 24
\BOOKMARK [0][-]{chapter.2}{Description logics and biomedical knowledge \(Specification\)}{}% 25
\BOOKMARK [1][-]{section.2.1}{Introduction}{chapter.2}% 26
\BOOKMARK [1][-]{section.2.2}{Biomedical knowledge}{chapter.2}% 27
\BOOKMARK [2][-]{subsection.2.2.1}{Contemporary formalism in biomedical sciences}{section.2.2}% 28
\BOOKMARK [3][-]{subsubsection.2.2.1.1}{Formalism varies among natural sciences}{subsection.2.2.1}% 29
\BOOKMARK [3][-]{subsubsection.2.2.1.2}{Organisms as complex machines}{subsection.2.2.1}% 30
\BOOKMARK [2][-]{subsection.2.2.2}{Requirements for biomedical knowledge formalisation}{section.2.2}% 31
\BOOKMARK [3][-]{subsubsection.2.2.2.1}{Mathematical framework}{subsection.2.2.2}% 32
\BOOKMARK [3][-]{subsubsection.2.2.2.2}{Definitions}{subsection.2.2.2}% 33
\BOOKMARK [3][-]{subsubsection.2.2.2.3}{Hierarchies and abstraction}{subsection.2.2.2}% 34
\BOOKMARK [3][-]{subsubsection.2.2.2.4}{Distributed and scalable}{subsection.2.2.2}% 35
\BOOKMARK [3][-]{subsubsection.2.2.2.5}{Molecular dynamism}{subsection.2.2.2}% 36
\BOOKMARK [1][-]{section.2.3}{Description logics for biomedical knowledge representation}{chapter.2}% 37
\BOOKMARK [2][-]{subsection.2.3.1}{Problems addressed by description logics}{section.2.3}% 38
\BOOKMARK [2][-]{subsection.2.3.2}{Expressivity and complexity}{section.2.3}% 39
\BOOKMARK [2][-]{subsection.2.3.3}{DLs' components and relation to life sciences}{section.2.3}% 40
\BOOKMARK [3][-]{subsubsection.2.3.3.1}{Description logics core entities}{subsection.2.3.3}% 41
\BOOKMARK [3][-]{subsubsection.2.3.3.2}{Axioms}{subsection.2.3.3}% 42
\BOOKMARK [3][-]{subsubsection.2.3.3.3}{Constructors}{subsection.2.3.3}% 43
\BOOKMARK [2][-]{subsection.2.3.4}{Reasoning services}{section.2.3}% 44
\BOOKMARK [2][-]{subsection.2.3.5}{The Web Ontology Language 2 \(OWL2\)}{section.2.3}% 45
\BOOKMARK [1][-]{section.2.4}{Implementation with life-science information}{chapter.2}% 46
\BOOKMARK [2][-]{subsection.2.4.1}{Integration with biomedical ontologies}{section.2.4}% 47
\BOOKMARK [3][-]{subsubsection.2.4.1.1}{Open Biomedical Ontologies \(OBO\)}{subsection.2.4.1}% 48
\BOOKMARK [3][-]{subsubsection.2.4.1.2}{Approximations and assumptions}{subsection.2.4.1}% 49
\BOOKMARK [2][-]{subsection.2.4.2}{Integration with databases}{section.2.4}% 50
\BOOKMARK [2][-]{subsection.2.4.3}{Brain library - implementing programmatic solutions}{section.2.4}% 51
\BOOKMARK [1][-]{section.2.5}{Summary}{chapter.2}% 52
\BOOKMARK [0][-]{chapter.3}{The Functional Therapeutic Chemical Classification System \(Implementation\)}{}% 53
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 54
\BOOKMARK [1][-]{section.3.2}{Method and definitions}{chapter.3}% 55
\BOOKMARK [2][-]{subsection.3.2.1}{Source code}{section.3.2}% 56
\BOOKMARK [2][-]{subsection.3.2.2}{Categories creation}{section.3.2}% 57
\BOOKMARK [3][-]{subsubsection.3.2.2.1}{Mode of Action categories}{subsection.3.2.2}% 58
\BOOKMARK [3][-]{subsubsection.3.2.2.2}{Mechanism of Action categories}{subsection.3.2.2}% 59
\BOOKMARK [2][-]{subsection.3.2.3}{Equivalent definitions}{section.3.2}% 60
\BOOKMARK [3][-]{subsubsection.3.2.3.1}{Regulatory pattern}{subsection.3.2.3}% 61
\BOOKMARK [3][-]{subsubsection.3.2.3.2}{Functional pattern}{subsection.3.2.3}% 62
\BOOKMARK [2][-]{subsection.3.2.4}{Data integration}{section.3.2}% 63
\BOOKMARK [3][-]{subsubsection.3.2.4.1}{Drugbank}{subsection.3.2.4}% 64
\BOOKMARK [3][-]{subsubsection.3.2.4.2}{Gene Ontology Annotations \(GOA\)}{subsection.3.2.4}% 65
\BOOKMARK [2][-]{subsection.3.2.5}{Knowledge base classification}{section.3.2}% 66
\BOOKMARK [2][-]{subsection.3.2.6}{Evaluation methodology}{section.3.2}% 67
\BOOKMARK [3][-]{subsubsection.3.2.6.1}{Evaluation Points}{subsection.3.2.6}% 68
\BOOKMARK [3][-]{subsubsection.3.2.6.2}{True Positives}{subsection.3.2.6}% 69
\BOOKMARK [3][-]{subsubsection.3.2.6.3}{False Negatives}{subsection.3.2.6}% 70
\BOOKMARK [3][-]{subsubsection.3.2.6.4}{False Positives}{subsection.3.2.6}% 71
\BOOKMARK [3][-]{subsubsection.3.2.6.5}{Precision}{subsection.3.2.6}% 72
\BOOKMARK [3][-]{subsubsection.3.2.6.6}{Recall}{subsection.3.2.6}% 73
\BOOKMARK [2][-]{subsection.3.2.7}{Semantic similarity}{section.3.2}% 74
\BOOKMARK [2][-]{subsection.3.2.8}{Mode of action similarity against indication}{section.3.2}% 75
\BOOKMARK [2][-]{subsection.3.2.9}{Knowledge base specification}{section.3.2}% 76
\BOOKMARK [3][-]{subsubsection.3.2.9.1}{Core FTC classes}{subsection.3.2.9}% 77
\BOOKMARK [3][-]{subsubsection.3.2.9.2}{Core FTC properties}{subsection.3.2.9}% 78
\BOOKMARK [1][-]{section.3.3}{The classification}{chapter.3}% 79
\BOOKMARK [1][-]{section.3.4}{Evaluation}{chapter.3}% 80
\BOOKMARK [1][-]{section.3.5}{Exploration}{chapter.3}% 81
\BOOKMARK [2][-]{subsection.3.5.1}{Polypharmacology spectrum}{section.3.5}% 82
\BOOKMARK [2][-]{subsection.3.5.2}{Drugs with similar functions have similar indications}{section.3.5}% 83
\BOOKMARK [1][-]{section.3.6}{Discussion}{chapter.3}% 84
\BOOKMARK [2][-]{subsection.3.6.1}{Biological assumptions}{section.3.6}% 85
\BOOKMARK [2][-]{subsection.3.6.2}{Interpreting the evaluation}{section.3.6}% 86
\BOOKMARK [1][-]{section.3.7}{Summary}{chapter.3}% 87
\BOOKMARK [0][-]{chapter.4}{Systematic drug repositioning analysis}{}% 88
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 89
\BOOKMARK [1][-]{section.4.2}{Structure, function and indication of drugs}{chapter.4}% 90
\BOOKMARK [2][-]{subsection.4.2.1}{Structural descriptor selection}{section.4.2}% 91
\BOOKMARK [2][-]{subsection.4.2.2}{Dissimilar structures have dissimilar functions}{section.4.2}% 92
\BOOKMARK [2][-]{subsection.4.2.3}{The more specific an indication is, the more similar the function and structure are}{section.4.2}% 93
\BOOKMARK [2][-]{subsection.4.2.4}{Isolation of drug repositioning hypotheses}{section.4.2}% 94
\BOOKMARK [1][-]{section.4.3}{Open drug repositioning hypotheses}{chapter.4}% 95
\BOOKMARK [2][-]{subsection.4.3.1}{Relationship between therapeutic areas}{section.4.3}% 96
\BOOKMARK [2][-]{subsection.4.3.2}{Drug repositioning for hypertension and the cardiovascular system}{section.4.3}% 97
\BOOKMARK [3][-]{subsubsection.4.3.2.1}{Antihypertensives}{subsection.4.3.2}% 98
\BOOKMARK [3][-]{subsubsection.4.3.2.2}{Calcium channel blockers}{subsection.4.3.2}% 99
\BOOKMARK [3][-]{subsubsection.4.3.2.3}{Adrenergic receptor antagonists}{subsection.4.3.2}% 100
\BOOKMARK [3][-]{subsubsection.4.3.2.4}{Alpha-2 agonists}{subsection.4.3.2}% 101
\BOOKMARK [3][-]{subsubsection.4.3.2.5}{Diuretics}{subsection.4.3.2}% 102
\BOOKMARK [3][-]{subsubsection.4.3.2.6}{Renin-angiotensin system}{subsection.4.3.2}% 103
\BOOKMARK [3][-]{subsubsection.4.3.2.7}{Peripheral vasodilators}{subsection.4.3.2}% 104
\BOOKMARK [2][-]{subsection.4.3.3}{Repositioning for Alzheimerâ€™s disease}{section.4.3}% 105
\BOOKMARK [1][-]{section.4.4}{Summary}{chapter.4}% 106
\BOOKMARK [1][-]{section.4.5}{Methods}{chapter.4}% 107
\BOOKMARK [2][-]{subsection.4.5.1}{Structural fingerprints calculation}{section.4.5}% 108
\BOOKMARK [2][-]{subsection.4.5.2}{Structural similarity between drugs}{section.4.5}% 109
\BOOKMARK [2][-]{subsection.4.5.3}{Agreement between fingerprinting methodologies}{section.4.5}% 110
\BOOKMARK [2][-]{subsection.4.5.4}{Kernel density plots}{section.4.5}% 111
\BOOKMARK [2][-]{subsection.4.5.5}{Web application related to drug repositioning hypotheses}{section.4.5}% 112
\BOOKMARK [2][-]{subsection.4.5.6}{Filtering of drug repositioning hypotheses}{section.4.5}% 113
\BOOKMARK [2][-]{subsection.4.5.7}{Filtering of relationships between therapeutic areas}{section.4.5}% 114
\BOOKMARK [0][-]{chapter.5}{Outlook and future work}{}% 115
\BOOKMARK [1][-]{section.5.1}{Work performed in the context of the drug discovery process}{chapter.5}% 116
\BOOKMARK [1][-]{section.5.2}{Comparison against functional genomics}{chapter.5}% 117
\BOOKMARK [1][-]{section.5.3}{Biomedical knowledge: towards a simpler representation}{chapter.5}% 118
\BOOKMARK [1][-]{section.5.4}{Off-label uses and clinical drug repositioning}{chapter.5}% 119
\BOOKMARK [0][-]{chapter*.83}{Bibliography}{}% 120
\BOOKMARK [0][-]{appendix.A}{Extra Information}{}% 121
